Gene therapy for hemophilia.
Hemophilia A and B are X-linked genetic disorders caused by deficiency of the coagulation factors VIII and IX, respectively. Because of the health hazards and costs of current product replacement therapy, much effort is devoted to the development of gene therapy for these disorders. Approaches to gene therapy for the hemophilias include: ex vivo gene therapy in which cells from the intended recipients are explanted, genetically modified to secrete Factor VIII or IX, and reimplanted into the donor; in vivo gene therapy in which Factor VIII or IX encoding vectors are directly injected into the recipient; and non-autologous gene therapy in which universal cell lines engineered to secrete Factor VIII or IX are enclosed in immuno-protective devices before implantation into recipients. Research into these approaches is aided by the many murine and canine models available. While problems of achieving high and sustained levels of factor delivery, and issues related to efficacy, safety and cost are still to be resolved, progress in gene therapy for the hemophilias has been encouraging and is likely to reach human clinical trial in the foreseeable future.
Hortelano
G
G
Department of Pathology, McMaster University, Hamilton, Ontario, Canada.
Chang
P L
PL
D000818:Animals; D016503:Drug Delivery Systems; D005164:Factor IX / Q000235:genetics / Q000627:therapeutic use; D005169:Factor VIII / Q000235:genetics / Q000627:therapeutic use; D005818:Genetic Engineering; D015316:Genetic Therapy; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans
D005169:Factor VIII; D005164:Factor IX